Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

医学 利西塞纳泰德 艾塞那肽 评论文章 利拉鲁肽 临床试验 疾病 内科学 生物信息学 免疫学 内分泌学 糖尿病 2型糖尿病 生物 病理
作者
Saleh Hadi Alharbi
出处
期刊:Therapeutic Advances in Endocrinology and Metabolism [SAGE Publishing]
卷期号:15: 20420188231222367-20420188231222367 被引量:217
标识
DOI:10.1177/20420188231222367
摘要

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic agents with potent anti-inflammatory properties and diverse clinical implications. This in-depth review article explores the mechanisms behind the anti-inflammatory actions of GLP-1RAs and assesses their prospective applicability in a wide range of disease scenarios. The current review establishes the significance of comprehending the anti-inflammatory role of GLP-1RAs and identifies pertinent research gaps. A concise overview of inflammation and its clinical consequences underscores the critical need for effective anti-inflammatory interventions. Subsequently, the article elucidates the intricate mechanisms through which GLP-1RAs modulate immune cell signaling and regulate the nuclear factor-kappa B (NF-κB) pathway. Detailed discussions encompass their impact on inflammatory responses, cytokine production, and attenuation of oxidative stress. The exposition is substantiated by a collection of pertinent examples and an extensive array of references from both preclinical and clinical investigations. The historical trajectory of GLP-1RA drugs, including exenatide, lixisenatide, liraglutide, and semaglutide, is traced to delineate their development as therapeutic agents. Moreover, the review emphasizes the therapeutic potential of GLP-1RAs in specific disease contexts like type 2 diabetes, a neurodegenerative disorder, and inflammatory bowel disease (IBD), shedding light on their anti-inflammatory effects through rigorous examination of preclinical and clinical studies. The article also provides an outlook on future perspectives for GLP-1RAs, encompassing the domains of diabetes, neurodegenerative diseases, and IBD. In conclusion, GLP-1RAs exhibit substantial anti-inflammatory effects, rendering them promising therapeutic agents with broad clinical implications. They are very useful in a wide variety of diseases because they regulate immunological responses, block NF-κB activation, and decrease production of pro-inflammatory cytokines. Ongoing research endeavors aim to optimize their therapeutic use, delineate patient-specific treatment paradigms, and explore novel therapeutic applications. GLP-1RAs represent a significant breakthrough in anti-inflammatory therapy, offering novel treatment options, and improved patient outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei的应助被小豆糕采纳,获得10
刚刚
邱邱科研发布了新的文献求助10
刚刚
丘比特的应助被elysia采纳,获得10
1秒前
思源的应助被风吹麦浪采纳,获得10
1秒前
香蕉觅云的应助被风吹麦浪采纳,获得10
1秒前
今后的应助被风吹麦浪采纳,获得30
1秒前
Lin关闭了Lin的文献求助
2秒前
2秒前
qingqingdandan完成签到 ,获得积分10
2秒前
2秒前
ccc关闭了ccc的文献求助
3秒前
3秒前
5秒前
zz完成签到,获得积分10
5秒前
duck发布了新的文献求助10
5秒前
5秒前
黑米粥发布了新的文献求助200
6秒前
ding的应助被汤汤采纳,获得10
6秒前
王明磊完成签到 ,获得积分10
6秒前
白辉发布了新的文献求助10
6秒前
7秒前
7秒前
7秒前
滕靖完成签到,获得积分10
7秒前
9秒前
wanwusheng完成签到,获得积分10
9秒前
852的应助被周依依采纳,获得10
10秒前
zhscu完成签到,获得积分10
10秒前
无极微光的应助被ZZ_star采纳,获得20
10秒前
11秒前
花未稀发布了新的文献求助10
11秒前
11秒前
12秒前
旦斯特尼发布了新的文献求助10
12秒前
Joseph0209发布了新的文献求助10
12秒前
小马甲的应助被吱吱采纳,获得10
12秒前
Changhiwi完成签到 ,获得积分10
13秒前
rd_z完成签到,获得积分10
13秒前
13秒前
在游的客完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611